Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Granger

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Biopharmaceutical Statistics|June 13, 2022
Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trialsAriadna Garcia, Vidhya Balasubramanian, Justin Lee, et al.
Circulation|January 22, 2024
Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI TrialMark C Petrie, Jean L Rouleau, Brian Claggett, et al.
Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
JAMA Cardiology|September 10, 2025
Approach to the Postmarket Evaluation of Consumer Wearable TechnologiesKrishna Pundi, Sanjeev Bhavnani, Clark Seninger, et al.
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
The New England Journal of Medicine|May 18, 2017
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular DiseaseA Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Biopharmaceutical Statistics|June 13, 2022
Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trialsAriadna Garcia, Vidhya Balasubramanian, Justin Lee, et al.
Circulation|January 22, 2024
Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI TrialMark C Petrie, Jean L Rouleau, Brian Claggett, et al.
Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
JAMA Cardiology|September 10, 2025
Approach to the Postmarket Evaluation of Consumer Wearable TechnologiesKrishna Pundi, Sanjeev Bhavnani, Clark Seninger, et al.
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
European Journal of Heart Failure|April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristicsKarola S Jering, Brian Claggett, Marc A Pfeffer, et al.
Circulation|November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI TrialRoxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
The New England Journal of Medicine|May 18, 2017
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular DiseaseA Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, et al.
Pageof 4